Exelon
(Rivastigmine)ApprovedSmall molecule
NovartisRivastigmine is used to treat memory loss and thinking problems in people with Alzheimer's disease or Parkinson's disease by helping to preserve a chemical in the brain that is important for memory and learning.[2] Exelon is currently approved and in use across 18 indications[4].[1]
Exelon is one of 404 small molecule programs targeting Methamphetamine Dependence. It is currently in Approved.
18
Indications
63
Total Trials
3
Active Trials
403
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 18 indications
Competition
Competitive Landscape
279 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Actos
TakedaPhase 3
Farxiga
AstraZenecaPhase 3
Provigil
NNuvo Research GmbH
Phase 3
Xarelto
WWim Janssens
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Donepezil Hydrochloride
EisaiPhase 3
Statins
SanofiPhase 3
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alzheimer's Disease15 trials
Show 12 more trials
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
Completed·—·N/A·NCT01380288·300 enrolled
Delirium6 trials
Cognitive impairment5 trials
Dementia3 trials
Mild to Moderate Alzheimer's Disease3 trials
24 more indications
Down syndrome2 trials
Rivastigmine Study in Adolescents With Down Syndrome
Completed·—·Phase 1/2·NCT01084135·42 enrolled
Neuromodulation2 trials
Alzheimer's Disease (AD)2 trials
Vascular Dementia2 trials
Trial2 trials
Progressive Supranuclear Palsy2 trials
Brain Injury1 trial
Hallucinations1 trial
Cognition1 trial
Methamphetamine Dependence1 trial
Rivastigmine as a Treatment for Methamphetamine Dependence
Completed·—·Phase 1·NCT01073319·17 enrolled
Double-blind1 trial
Fed1 trial
Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions
Completed·—·Phase 1·NCT01146041·44 enrolled
Alzheimer disease1 trial
Fasting Conditions1 trial
Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions
Completed·—·Phase 1·NCT01146067·44 enrolled
Treatment1 trial
Efficacy1 trial
Cocaine Dependence1 trial
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Completed·—·Phase 1·NCT01030692·72 enrolled
Parkinson disease1 trial
Post-Operative Delirium1 trial
Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.
Completed·—·Phase 4·NCT02413554·62 enrolled
Regulatory
FDA Approval Timeline[5]
Apr 21, 2000
EXELON
NDA NDA020823
Apr 21, 2000
EXELON
NDA NDA021025
Jul 6, 2007
EXELON
NDA NDA022083
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Exelon drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rivastigmine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]